Tucatinib improved survival for women in the HER2CLIMB trial, including some whose cancer had spread to the brain. Trastuzumab deruxtecan improved survival and shrank many tumors in the DESTINY-Breast01 trial, which led to its accelerated approval.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/37SIHZf
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/37SIHZf